[go: up one dir, main page]

PE20040288A1 - Composiciones farmaceuticas de acido 5-metil-2-(2'-cloro-6'-fluoroanilino)fenilacetico - Google Patents

Composiciones farmaceuticas de acido 5-metil-2-(2'-cloro-6'-fluoroanilino)fenilacetico

Info

Publication number
PE20040288A1
PE20040288A1 PE2003000221A PE2003000221A PE20040288A1 PE 20040288 A1 PE20040288 A1 PE 20040288A1 PE 2003000221 A PE2003000221 A PE 2003000221A PE 2003000221 A PE2003000221 A PE 2003000221A PE 20040288 A1 PE20040288 A1 PE 20040288A1
Authority
PE
Peru
Prior art keywords
chloro
methyl
fluoroanilino
pharmaceutical compositions
phenylacetic acid
Prior art date
Application number
PE2003000221A
Other languages
English (en)
Inventor
Anees Abdulquadar Karnachi
Jurij Holinej
Yatindra Joshi
Maha Y Khaled
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20040288A1 publication Critical patent/PE20040288A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA SOLIDA PARA TRATAR UN DESORDEN O CONDICION DEPENDIENTE DE LA CICLOOXIGENASA-2, COMPRENDIDA ENTRE 200mg Y 400mg DE ACIDO 5-METIL-2-(2'-CLORO-6'-FLUOROANILINO)FENILACETICO O LUMIRACOXIB, SIENDO EL NIVEL DE HUMEDAD RESIDUAL (LOD) DE ESTA COMPOSICION ENTRE 1.5% Y 5% APROXIMADAMENTE, PUDIENDO SER TABLETAS O TABLETAS RECUBIERTAS CON PELICULAS.TAMBIEN SE REFIERE A GRANULACIONES SECAS UTILES PARA FABRICAR COMPOSICIONES CONSTITUIDO POR LUMIRACOXIB, CELULOSA MICROCRISTALINA, LACTOSA Y CROSCAMELOSA DE SODIO, DONDE EL NIVEL DE HUMEDAD RESIDUAL ES ENTRE 2.5% A 4.5% APROXIMADAMENTE U OTRAS GRANULACIONES SECAS QUE COMPRENDE LUMIRACOXIB, CROSCAMELOSA DE SODIO Y POVIDONA CON UN LOD DE 1.5% A 4% APROXIMADAMENTE.TAMBIEN SE REFIERE A UN METODO PARA ESTABILIZAR EL COMPUESTO EN UNA COMPOSICION FARMACEUTICA
PE2003000221A 2002-03-07 2003-03-06 Composiciones farmaceuticas de acido 5-metil-2-(2'-cloro-6'-fluoroanilino)fenilacetico PE20040288A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36235102P 2002-03-07 2002-03-07

Publications (1)

Publication Number Publication Date
PE20040288A1 true PE20040288A1 (es) 2004-06-24

Family

ID=27789154

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000221A PE20040288A1 (es) 2002-03-07 2003-03-06 Composiciones farmaceuticas de acido 5-metil-2-(2'-cloro-6'-fluoroanilino)fenilacetico

Country Status (20)

Country Link
US (4) US20050123604A1 (es)
EP (1) EP1492520A1 (es)
JP (1) JP2005519097A (es)
KR (1) KR20040089654A (es)
CN (1) CN1330300C (es)
AR (1) AR038747A1 (es)
AU (1) AU2003227039B2 (es)
BR (1) BR0308156A (es)
CA (1) CA2476744A1 (es)
CO (1) CO5650241A2 (es)
EC (1) ECSP045244A (es)
MX (1) MXPA04008665A (es)
NO (1) NO20044164L (es)
NZ (1) NZ534587A (es)
PE (1) PE20040288A1 (es)
PL (1) PL370907A1 (es)
RU (1) RU2318497C2 (es)
TW (1) TW200305443A (es)
WO (1) WO2003074041A1 (es)
ZA (1) ZA200406226B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8951996B2 (en) * 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
EA033102B1 (ru) * 2017-08-21 2019-08-30 Общество с ограниченной ответственностью "Фармамед" Фармацевтическая композиция с модифицированным отсроченным и длительным высвобождением, содержащая аспарагинаты
WO2023113650A1 (ru) * 2021-12-15 2023-06-22 Владимир Евгеньевич НЕБОЛЬСИН Фармацевтическая композиция 1-[2-(1-метилимидазол-4-ил)-этил]пергидроазин-2,6-дион для терапии заболеваний верхних дыхательных путей

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3346525C2 (de) * 1983-12-22 1987-03-19 A. Nattermann & Cie GmbH, 5000 Köln Pharmazeutische Zubereitung mit speziellen 1,2-Diacyl-glycero-3-phosphocholinen zur Behandlung von Erkrankungen im Magen-Darmbereich
KR100208979B1 (ko) * 1992-06-12 1999-07-15 야스이 쇼사꾸 기도내 투여용 제제
JPH08511009A (ja) * 1993-06-08 1996-11-19 チバ−ガイギー アクチェンゲゼルシャフト ジクロフェナックを含有する経口固体剤形の製造方法
IL126899A (en) * 1996-05-17 2004-03-28 Merck & Co Inc Preparations for once-daily treatment of diseases mediated by cyclooxygenase-2
CO4960662A1 (es) * 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
DE19931708A1 (de) * 1999-07-08 2001-01-18 Bayer Ag Verfahren zur Herstellung schnell zerfallender, fester pharmazeutischer Zubereitungen
AR030630A1 (es) * 2000-09-11 2003-08-27 Novartis Ag Composiciones farmaceuticas
US20030114527A1 (en) * 2001-08-31 2003-06-19 Karnachi Anees Abdulquadar Pharmaceutical composition

Also Published As

Publication number Publication date
BR0308156A (pt) 2005-01-04
CA2476744A1 (en) 2003-09-12
KR20040089654A (ko) 2004-10-21
AU2003227039A1 (en) 2003-09-16
US20050123604A1 (en) 2005-06-09
AR038747A1 (es) 2005-01-26
AU2003227039B9 (en) 2003-09-16
US20030171437A1 (en) 2003-09-11
ECSP045244A (es) 2004-09-28
NZ534587A (en) 2007-08-31
TW200305443A (en) 2003-11-01
PL370907A1 (en) 2005-05-30
US20090149543A1 (en) 2009-06-11
ZA200406226B (en) 2005-06-23
CO5650241A2 (es) 2006-06-30
US20070087051A1 (en) 2007-04-19
NO20044164L (no) 2004-09-30
MXPA04008665A (es) 2004-12-06
RU2004129770A (ru) 2005-05-10
JP2005519097A (ja) 2005-06-30
EP1492520A1 (en) 2005-01-05
CN1330300C (zh) 2007-08-08
AU2003227039B2 (en) 2007-04-19
RU2318497C2 (ru) 2008-03-10
WO2003074041A1 (en) 2003-09-12
CN1638752A (zh) 2005-07-13

Similar Documents

Publication Publication Date Title
BR0210267A (pt) Composição farmacêutica sólida, processo para preparar a mesma, conjunto para o tratamento de obesidade, utilização da composição, processo de tratamento de obesidade e inibidor de lìpases
UY25322A1 (es) Compuestos de tiourea y benzamida,composiciones y metodos para tratar y prevenir enfermedades inflamatorias y aterosclerosis
DK50487A (da) Phenoliske thioethere og farmaceutisk acceptable salte deraf samt dens anvendelse som lipoxygenaseinhibitorer
BR9806060A (pt) Composto, composição farmacêutica e processos para tratar um paciente sofrendo de um estado doentio, para inibir o fator xa, e, para inibir a formação de trombina.
BR9913239A (pt) Comprimido bioadesivo bucal de liberação prolongada
BR9911579A (pt) Uso de um composto antimicrobiano para desinfecção
WO2008093686A1 (ja) 非ステロイド系抗炎症薬と有機アミン化合物との塩とその用途
PE20040972A1 (es) Intermedio de formulacion aceptablemente no higroscopico que comprende un farmaco higroscopico
AR011106A1 (es) COMPOSICIoN FARMACÉUTICA PARA EL TRAMIENTO O PREVENCI.ON DE LA DIABETES MELLITUS TIPO 2,
SV1997000026A (es) Composiciones farmaceuticas para el tratamiento de la rinitis
ATE147981T1 (de) Verabreichung von lamotrigin zur behandlung von neuro-aids
BRPI0415753A (pt) método para tratamento e prevenção da inflamação respiratória com um inibidor de ciclooxigenase-2 em associação com um inibidor de fosfodiesterase 4 e composições que os contêm
CO5560554A2 (es) Composicion farmaceutica que comprende lumiracoxib
BR9910445A (pt) Preparação farmacêutica
BR9713921A (pt) Composto, composição farmacêutica, processo para tógico capaz de ser modulado através da inibição do fator xa
PE20040288A1 (es) Composiciones farmaceuticas de acido 5-metil-2-(2'-cloro-6'-fluoroanilino)fenilacetico
PE20020351A1 (es) Composiciones farmaceuticas que comprenden acido 5-metil-2-(2'-cloro-6'-fluoroanilino)fenilacetico como inhibidor de la ciclooxigenasa-2
NO20054408D0 (no) 3(2-fenyl-oksazol-4-yl-metoksy)-cykloheksylmetoksyeddiksyrederivater og lignende forbindelser som PPAR-modulatorer for behandling av type 2 diabetes og arterosklerose
CL2004000512A1 (es) Compuestos derivados del acido 3-{1-(3-(1,3-benzotiazol-6-il) propilcarbamoil]cicloalquil}propanoico, inhibidores de endopeptidasa neutra; composicion farmaceutica que los comprende; y su uso para tratar hipertension, insuficiencia cardiaca, diabetes
CL2000002938A1 (es) Cristales del acido (e)-4-[4-(5-metil-2-fenil-4-oxazolilmetoxi)benciloxiimino]-4-fenilbutirico, composicion farmaceutica que los comprende y su uso en el tratamiento o prevencion de la diabetes mellitus, hiperlipemia, disminucion en la tolerancia a la glucosa, enfermedades inflamatorias, arteriosclerosis.
PT98604A (pt) Processo para a preparacao de uma solucao estavel de hipoclorito de sodio
DK0701449T3 (da) Fremgangsmåde til fremstilling af en oral fast dosisform indeholdende diclofenac
BR9707931A (pt) Derivados sulfurados comportando um ligação amida seu processo de prepara sua aplicação a título de medicamentos e as composições farmacêuticas que os contêm
ES2079817T3 (es) Composicion para el tratamiento de las uñas que comprende un aminoacido sulfurado.
BRPI0414819A (pt) pró-fármacos de aminoácidos com afinidade para a proteìna alfa2delta

Legal Events

Date Code Title Description
FC Refusal